-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
ARE reported Q1 revenue of $671M (-11.5% Y/Y and $25M below consensus) vs. $754M a year ago. Rental income declined 12.1% to $653M, reflecting lower occupancy and significant pricing pressure on lease renewals across the portfolio. Rental rate changes on renewals and re-leasing showed a steep 15.0% decline (-15.8% cash basis), a dramatic reversal from the -5.5% cash renewal rate in Q4 2025. Management updated cash rental rate guidance to -14% to -7%, declining a further 300 bps since February as market conditions deteriorated. We expect continued pressure on re-leasing growth in full-year 2026 as ARE continues to optimize its portfolio of properties amid challenging life science market dynamics. The significant deterioration in renewal spreads from Q4 2025 to Q1 2026 highlights the difficult operating environment facing life science real estate, with both occupancy headwinds and rental rate pressures creating a challenging backdrop for near-term financial performance and cash flow generation.